William Blair Reiterates Outperform Rating on Kinnate Biopharma (KNTE), Sees Potential for Significant Upside in Shares
Tweet Send to a Friend
William Blair analyst Tim Lugo reiterated an Outperform rating on Kinnate Biopharma (NASDAQ: KNTE).The analyst comments: "Despite holding what we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
